Soru

Zorluk: OrtaDepressive Disorders

A 45-year-old man is diagnosed with a first episode of severe, non-psychotic major depressive disorder. He is medically healthy and has no previous psychiatric treatment history. According to standard stepped-care guidelines for major depressive disorder, arrange the following therapeutic management steps in the most appropriate chronological sequence, assuming the patient exhibits only a partial response to each consecutive intervention.

  1. 1Initiate first-line pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI).
  2. 2Optimize the dosage of the initial SSRI to the maximum tolerated level.
  3. 3Augment the current regimen with a second-generation antipsychotic or lithium.
  4. 4Refer the patient for electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS).

Cevap

The correct sequence for managing treatment-resistant depression is to first initiate first-line monotherapy, optimize its dosage, augment with a second agent upon partial response, and finally consider neuromodulation such as ECT if pharmacological options are exhausted.
The stepped-care approach to major depressive disorder prioritizes efficacy while minimizing side effects and polypharmacy. It begins with a single well-tolerated agent. If the response is partial, the clinician's first obligation is to ensure the dose is optimized to confirm whether it is a true failure at therapeutic levels. If partial response persists despite dose optimization, augmentation (e.g., with a second-generation antipsychotic) is indicated to boost efficacy. Finally, if the patient fails multiple adequate medication trials, they are deemed to have treatment-resistant depression, at which point interventional treatments like ECT become appropriate.

Adım Adım Çözüm

1
Establish the diagnosis and select initial therapy.
Initiate first-line pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI).
SSRIs are standard first-line agents with a favorable efficacy and side-effect profile for non-psychotic major depressive disorder.
2
Assess clinical response at 4 to 8 weeks.
Optimize the dosage of the initial SSRI to the maximum tolerated level.
A common cause of perceived treatment failure is an inadequate dose; maximizing the dose ensures an adequate trial before discarding the medication.
3
Re-evaluate after dose optimization reveals only partial improvement.
Augment the current regimen with a second-generation antipsychotic or lithium.
For partial responders to an adequate monotherapy trial, adding an augmenting agent targets residual symptoms without discarding the partial benefit of the SSRI.
4
Assess for treatment-resistant depression after multiple failed pharmacological trials.
Refer the patient for electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS).
When standard step-care psychopharmacology fails, the patient meets criteria for treatment-resistant depression, indicating the need for highly effective neuromodulation.

Anahtar Kavram

Stepped-care management of Major Depressive Disorder involves initial monotherapy, dose optimization, augmentation or switching strategies, and ultimately neuromodulation for treatment-resistant cases.
Bu soruyu puanla